Abstract
Adjuvant bisphosphonate therapy is recommended in postmenopausal women with intermediate or high risk EBC. Bisphophonates improve breast cancer outcomes and also protect against bone loss from adjuvant aromatase inhibitors (AI). The increasing use of extended adjuvant AIs beyond 5 years has implications for bone health. There is currently no specific guidance for BMD monitoring in patients on extended endocrine therapy.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
